Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant chemotherapy in operable NSCLC (stage IB–IIIA/T3)
2006-003503-39Phase 3Completed
- Sponsor
- Finsen Centre
- Start
- Aug 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of docetaxel, carboplatin, cisplatin and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by Finsen Centre. Primary endpoint: survival. Started Aug 2006; status: completed.
02
Drugs
docetaxelcarboplatincisplatinvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-003503-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003503-39.